DE60200317D1 - Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff - Google Patents

Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff

Info

Publication number
DE60200317D1
DE60200317D1 DE60200317T DE60200317T DE60200317D1 DE 60200317 D1 DE60200317 D1 DE 60200317D1 DE 60200317 T DE60200317 T DE 60200317T DE 60200317 T DE60200317 T DE 60200317T DE 60200317 D1 DE60200317 D1 DE 60200317D1
Authority
DE
Germany
Prior art keywords
active ingredient
hci
formulation
controlled release
containing bupropion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60200317T
Other languages
English (en)
Other versions
DE60200317T2 (de
Inventor
Roberto Valducci
Tiziano Alighieri
Serozh Avanessian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valpharma SpA
Original Assignee
Valpharma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma SpA filed Critical Valpharma SpA
Publication of DE60200317D1 publication Critical patent/DE60200317D1/de
Application granted granted Critical
Publication of DE60200317T2 publication Critical patent/DE60200317T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60200317T 2001-07-09 2002-06-03 Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff Expired - Fee Related DE60200317T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI20011457 2001-07-09
IT2001MI001457A ITMI20011457A1 (it) 2001-07-09 2001-07-09 Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
CA002391691A CA2391691A1 (en) 2001-07-09 2002-06-26 Modified release pharmaceutical composition containing bupropion hci as active substance

Publications (2)

Publication Number Publication Date
DE60200317D1 true DE60200317D1 (de) 2004-05-06
DE60200317T2 DE60200317T2 (de) 2005-02-24

Family

ID=32991642

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60200317T Expired - Fee Related DE60200317T2 (de) 2001-07-09 2002-06-03 Formulierung mit gesteuerter Wirkstoffabgabe enthaltend Bupropion-HCI als Wirkstoff

Country Status (14)

Country Link
US (1) US20030134906A1 (de)
EP (1) EP1275383B1 (de)
JP (1) JP2003048828A (de)
AT (1) ATE262898T1 (de)
AU (1) AU5068202A (de)
BR (1) BR0202759A (de)
CA (1) CA2391691A1 (de)
DE (1) DE60200317T2 (de)
DK (1) DK1275383T3 (de)
ES (1) ES2219602T3 (de)
IL (1) IL149899A0 (de)
IT (1) ITMI20011457A1 (de)
NZ (1) NZ519844A (de)
PT (1) PT1275383E (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN192747B (de) * 2002-04-15 2004-05-15 Ranbaxy Lab Ltd
KR101087464B1 (ko) * 2003-08-08 2011-11-25 밸리언트 인터내셔널(바베이도스) 에스알엘 부프로피온 히드로클로라이드의 개질 방출형 정제
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393078A (en) * 1982-03-15 1983-07-12 Burroughs Wellcome Co. Bupropion and ethanol
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
JP2001527554A (ja) * 1997-05-07 2001-12-25 アルゴス ファーマシューティカル コーポレーション 抗うつ薬とｎｍｄａレセプター拮抗薬とを組み合わせる神経障害痛の治療用組成物及び治療方法
ES2248908T7 (es) * 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) * 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
CA2244097A1 (en) * 1998-08-21 2000-02-21 Bernard Charles Sherman Pharmaceutical composition comprising bupropion hydrochloride and fumaric acid
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
DK1275383T3 (da) 2004-05-24
ATE262898T1 (de) 2004-04-15
AU5068202A (en) 2003-01-16
NZ519844A (en) 2003-09-26
ITMI20011457A1 (it) 2003-01-09
EP1275383A1 (de) 2003-01-15
PT1275383E (pt) 2004-06-30
EP1275383B1 (de) 2004-03-31
ITMI20011457A0 (it) 2001-07-09
IL149899A0 (en) 2002-11-10
ES2219602T3 (es) 2004-12-01
US20030134906A1 (en) 2003-07-17
JP2003048828A (ja) 2003-02-21
BR0202759A (pt) 2004-05-11
DE60200317T2 (de) 2005-02-24
CA2391691A1 (en) 2003-12-26

Similar Documents

Publication Publication Date Title
NO20054164L (no) Immunoglobulinformulering og fremgangsmåte for fremstilling derav
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
PT1412384E (pt) Formulação estável de glp-1 modificado
BRPI0412241A (pt) formulação para medicamentos de proteìna sem adição de albumina de soro humano (hsa)
PL362797A1 (en) Medical aerosol formulations
CY1106943T1 (el) Υποδορια εμφυτευματα τα οποια εμφανιζουν περιορισμενη αρχικη αποδεσμευση του ενεργου συστατικου και ακολουθως γραμμικα μεταβαλλομενη εκτεταμενη αποδεσμευση
ATE334663T1 (de) Arzneimittelzusammensetzung mit verzögerter wirkstoffabgabe
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
PT1283700E (pt) Composicoes farmaceuticas de libertacao prolongada destinadas a administracao por via parental de compostos hidrofilos biologicamente activos
DE60211464D1 (de) Pharmazeutische formulierungen mit kontrollierter wirkstoff-freigabe enthaltend milchsäure-polymer, sowie deren herstellung
TW200503754A (en) HSA-free stabilized interferon liquid formulations
WO2007037795A3 (en) Stable aqueous protein or antibody pharmaceutical formulations and their preparation
DE60124294D1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
ATE286736T1 (de) Direktverpressbare matrix zur kontrollierten abgabe von einmaltäglichen dosen von clarithromycin
DE69716469D1 (de) Pharmazeutische zusammensetzung enthaltend ein osteogenese foerderndes mittel und ein polyethylen-glycol
NO20031409D0 (no) Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse
DE60329968D1 (de) Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren
DK1009380T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer
EA200901148A1 (ru) Подкожные имплантаты, высвобождающие активные компоненты в течение длительного периода времени
ATE262898T1 (de) Formulierung mit gesteuerter wirkstoffabgabe enthaltend bupropion-hci als wirkstoff
DE60316714D1 (de) Pharmazeutische formulierung enthaltend olanzapin
DE60108354D1 (de) 2H-1-Benzopyran-Derivative, Prozesse zu ihrer Herstellung und Pharmazeutische Zusammensetzungen
SE0001916D0 (sv) Novel formulation
ATE245974T1 (de) Pharmazeutische zusammensetzungen, bestimmt zur oralen verabreichung von phloroglucinol sowie deren herstellung
WO2005115346A3 (en) Pharmaceutical composition containing risperidone

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee